KOWA CO. LTD. 7807

Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension€3 million milestone payment due to Nicox, with a further milestone payment due upon approvalSubmission based on posit

KOWA–Amogy MoU Signing Amogy and KOWA sign memorandum of understanding (MoU) to provide ammonia cracking-based hydrogen supply in Japan. NEW YORK AND TOKYO, June 16, 2026 (GLOBE NEWSWIRE) -- Amogy, a provider of mature, scalable, and efficient ammonia-to-hydrogen and ammonia-to-power solutions, and KOWA Company, Ltd. (KOWA) today announced a partnership to bring ammonia cracking-based hydrogen supply solutions in Japan, following the signing of a Memorandum of Understanding (MoU) between the two

Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugat

KKR (KKR) and Taiyo Holdings announced that KJ005 Co., Ltd., an entity owned by investment funds managed by KKR, intends to make a tender offer to acquire all the common shares of Taiyo Holdings. Taiyo Holdings’ Board of Directors has resolved to support the Tender Offer. In addition, DIC Corporation, Taiyo Holdings’ largest shareholder, Kowa Co., Ltd., an asset management company affiliated with Taiyo Holdings’ founding family, and funds managed by Oasis Management Company Ltd. have each entere